ASCO 2017- Phase 3 ELOQUENT-2 study- Elotuzumab lenalidomide-dexamethasone vs Ld in relapsed-refractory MM

Background: Elotuzumab, an immunostimulatory monoclonal antibody, has a dual mechanism of action: directly activating NK cells and tagging myeloma cells for recognition/death via antibody-dependent ce... Author: InternationalMyelomaFoundation Added: 08/15/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts